Photo of Bishal Gyawali and Nina Niu Sanford
Mar 21, 2024, 16:09
Bishal Gyawali: A pleasure to write this editorial with the brilliant Nina Niu Sanford on how to manage FCOI in oncology
Bishal Gyawali, Associate Professor and Medical Oncologist at
“Hot off the press in JCO Oncology Practice! It was a pleasure to write this editorial with the brilliant Nina Niu Sanford on how to manage FCOI in oncology. We make 4 specific recommendations, which we believe can move the needle in the right direction. It’s free to read.
This editorial was in response to this excellent article published by Schnog John-John about FCOI among oncologists in the Netherlands.
Our recommendations:
Here are our suggestions regarding general/personal payments to physicians from the industry. But before making any suggestions, if any system doesn’t yet have an open payments database tracking all financial payments to physicians from pharmaceutical companies, that is the first step.
Hello! We need an open payments database. Remember that this only improves transparency, doesn’t mitigate the consequences of FCOI per se. Here are our suggestions to address this-
Hello! We need an open payments database. Remember that this only improves transparency, doesn’t mitigate the consequences of FCOI per se. Here are our suggestions to address this-
- Authors of clinical practice guidelines like NCCN should have NO general payments from the industry.
- Leadership of professional societies including annual meeting presidents, educational track leads, and plenary discussants should have no FCOI.
- PIs of clinical trials should not be allowed to hold stocks for the company who is making the products being tested.
- People who write editorials for seminal trails in major journals should not have FCOI- at the very least not from the same company whose drug is being discussed.”
Source: Bishal Gyawali/X
Jul 26, 2024, 00:27